Catalyst
Slingshot members are tracking this event:
New Bristol-Myers Squibb Research on Opdivo (nivolumab) Monotherapy and in Combination With Yervoy (ipilimumab) to be presented at SMR 2016 Congress Reinforces Immuno-Oncology Leadership and Scientific Expertise in Melanoma
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BMY | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 09, 2016
Occurred Source:
https://www.melanomacongress.com/docs/2016_abstracts.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Opdivo, Nivolumab, Yervoy, Ipilimumab
